Cosmos Technical Center
Itabashi-ku, Tokyo, 174-0046, Japan
NCT Number: NCT01305057
The effects of topically applied pyridoxine tri-isopalmitate (P-IP) which stimulates filaggrin synthesis in keratinocytes, on skin hydration and barrier function were examined. Subjects were separated into two groups to examine the effect of P-IP. Subjects were treated with P-IP formulation on one side of the face and with a placebo formulation on the other side twice daily (morning and evening) for 28 days. All subjects gave written informed consent prior to the study. The skin hydration and TEWL (transepidermal water loss) were evaluated by measuring skin surface conductance with a skin hygrometer SKICON 200EX (I.B.S. ltd., Japan) and TEWL meter AS-CT1 (ASAHI BIOMED, Tokyo, Japan), respectively.
Looking for future studies?
Notify Me33 year–62 year
All sexes
Interventional
Not applicable
Itabashi-ku, Tokyo, 174-0046, Japan
It is expected that the long-term application of P-IP increase skin surface water contents and suppress TEWL.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2% dosage, oil-in-water emulsion, twice a day, 28 days
Time frame: Before application, 1 week, 2 week and 4 weeks after application
Subjects were treated with P-IP formulation on one side of the face and with a placebo formulation (without P-IP, oil-in-water emulsion type) on the other side twice daily (morning and evening) for 28 days. Skin surface water contents and TEWLs were measured at the time frame described above and the results were analyzed as a change from a value of before-application at each measurement.
Cosmos Technical Center
Industry
Human Use Test on Skin Hydration and Skin Barrier Function
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07725900
Dry Skin, Erythema
Semarang, Central Java, Indonesia
View Trial DetailsNCT06800755
Dry Skin, Pathological Conditions, Signs and Symptoms
Gdansk, Poland
View Trial DetailsNCT07393191
Cracked Skin, Dry Skin
San Martino Siccomario, Milano, Italy
View Trial DetailsNCT07360639
Dry Skin, Xerosis Cutis
Banda Aceh, Nanggore Aceh Darussalam, Indonesia
View Trial Details